Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy
New York Marriott Downtown
85 West Street at Albany Street
New York, New York 10006
Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy
Physicians' Education Resource

Schedule of Presentations:

Friday, October 16, 2009
07:30:00 Registration and Continental Breakfast
08:00:00 Welcome and Introductions
08:05:00 Presession Survey
08:05:00 Clinical Implications of Breast Cancer Heterogeneity
08:10:00 Pathologic and Genomic Heterogeneity Philip Bernard
08:40:00 HER2 Dependence Edith A Perez
09:00:00 ER Plasticity Rachel Schiff
09:20:00 Postsession Survey
09:25:00 Panel Discussion
09:45:00 Break
09:50:00 Luminal Breast Cancer
10:05:00 Presession Survey
10:15:00 Identification of and Targeted Therapies for High-Risk Luminal Breast Cancer Matthew Ellis
10:35:00 Proliferation Status and Benefit from Adjuvant Chemotherapy Jo Anne Zujewski
10:55:00 Which Node-Positive Patients Don't Benefit from Adjuvant Chemotherapy? TBA
11:15:00 Panel Discussion
11:35:00 Break
11:50:00 Lunch and Satellite Symposium (tentative)
11:55:00 Luminal Breast Cancer (continued)
12:50:00 Update on Adjuvant Endocrine Therapies Stephen E. Jones
13:10:00 Pharmacogenomics of Adjuvant Endocrine Therapy Frankie Ann Holmes
13:30:00 Managing the Bone Microenvironment in Early-Stage Breast Cancer Allan Lipton
13:50:00 Blocking Cross-Talk Between ER and Growth Factor Pathways Michael P. DiGiovanna
14:00:00 Postsession Survey
14:10:00 Panel Discussion
14:30:00 Break
14:35:00 HER2-Driven Breast Cancer
14:45:00 Presession Survey
14:55:00 New Insights into Adjuvant Therapy for HER2-Positive Breast Cancer TBA
15:15:00 Predicting and Overcoming Resistance to HER2-Targeted Therapy Lyndsay N Harris
15:35:00 Endocrine Therapy in HER2-Driven Breast Cancer: Is it Effective? Rachel Schiff
15:55:00 Postsession Survey
16:05:00 Panel Discussion
16:30:00 Adjourn
16:35:00 End of day 1
Saturday, October 17, 2009
07:30:00 Continental Breakfast
08:00:00 Biologic Insights into Angiogenesis: Implications for the Treatment of Early-Stage Breast Cancer Mark Pegram
08:05:00 Loco-Regional Therapy: Ongoing Controversies
08:30:00 Presession Survey
08:35:00 Evolving Options for Radiation After Breast-Conserving Surgery Richard C. Zellars
08:55:00 Post-Mastectomy Radiation in 1-3 Positive Nodes Bruce G Haffty
09:15:00 Can We Omit Axillary Dissection in SLN-Positive Breast Cancer? Eleftherios P. Mamounas
09:35:00 The Impact of Systemic Therapy on DCIS Outcomes Sandra M. Swain
09:55:00 The ISPY Trials: Initial Results and Directions for the Future Laura Esserman
10:15:00 Postsession Survey
10:20:00 Panel Discussion
10:40:00 Break
10:45:00 Basal Breast Cancer
11:00:00 Presession Survey
11:10:00 Role of Anthracyclines in the Treatment of Early-Stage Breast Cancer Clifford A. Hudis
11:30:00 Novel Targeted Therapeutic Strategies for Basal Breast Cancer Joyce O’Shaughnessy
11:50:00 Novel Cytotoxic Agents for Triple-Negative Breast Cancer Sandra M. Swain
12:10:00 Break
12:25:00 Lunch and Satellite Symposium (tentative)
13:00:00 Basal Breast Cancer (continued)
13:25:00 Optimizing Adjuvant Chemotherapy Regimens for High-Risk Breast Cancer Andrew Seidman
13:45:00 Do Steroid Hormones Drive ER-Negative Breast Cancer? Suzanne AW Fuqua
14:05:00 Postsession Survey
14:15:00 Panel Discussion
14:35:00 Break
14:40:00 Controversies in the Multidisciplinary Management of Patients Treated with Neoadjuvant Therapy
14:50:00 Presession Survey
14:55:00 Controversies in Systemic Therapy Andrew Seidman
15:15:00 Controversies in Radiation Therapy Lori J. Pierce
15:35:00 Controversies in Surgery Hiram S. Cody
15:55:00 Controversies in Reconstruction Joseph J. Disa
16:15:00 Postsession Survey
16:20:00 Panel Discussion
16:25:00 Clinical Debate: Hormone–Receptor-Positive Breast Cancer Requires Lifelong Endocrine Therapy
16:35:00 Point Frankie Ann Holmes
16:50:00 Counterpoint Debu Tripathy
17:05:00 Panel Discussion
17:15:00 Adjourn
Sunday, October 18, 2009
07:30:00 Ask the Faculty: Oncology Consultations Breakfast
09:00:00 From Preoperative Promise to High-Risk Adjuvant Trials: The Way Forward? TBA
09:20:00 Management of Male Breast Cancer David M. Euhus
09:40:00 Novel Biologic Agents with Promise for High-Risk Early Breast Cancer
09:45:00 Host Factors and Breast Cancer Outcomes
10:00:00 COX-2 and Other New Molecular Targets in Breast Cancer Treatment and Prevention Powel H. Brown
10:20:00 Should We Treat Hyperinsulinemia in Early Breast Cancer? Pamela J. Goodwin
10:40:00 Vitamin D and Breast Cancer Rowan Chlebowski
11:00:00 Update on Hereditary Breast Cancer Syndromes: Prophylaxis and Treatment Paula D Ryan
11:20:00 Closing Comments
11:30:00 Adjourn
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.